Anti-SYT9 monoclonal antibody

Anti-SYT9 antibody for FACS & in-vivo assay

Target products collectionGo to SYT9/SYT9 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1751-Ab-1/ GM-Tg-hg-MP1751-Ab-2Anti-Human SYT9 monoclonal antibodyHuman
GM-Tg-rg-MP1751-Ab-1/ GM-Tg-rg-MP1751-Ab-2Anti-Rat SYT9 monoclonal antibodyRat
GM-Tg-mg-MP1751-Ab-1/ GM-Tg-mg-MP1751-Ab-2Anti-Mouse SYT9 monoclonal antibodyMouse
GM-Tg-cynog-MP1751-Ab-1/ GM-Tg-cynog-MP1751-Ab-2Anti-Cynomolgus/ Rhesus macaque SYT9 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1751-Ab-1/ GM-Tg-felg-MP1751-Ab-2Anti-Feline SYT9 monoclonal antibodyFeline
GM-Tg-cang-MP1751-Ab-1/ GM-Tg-cang-MP1751-Ab-2Anti-Canine SYT9 monoclonal antibodyCanine
GM-Tg-bovg-MP1751-Ab-1/ GM-Tg-bovg-MP1751-Ab-2Anti-Bovine SYT9 monoclonal antibodyBovine
GM-Tg-equg-MP1751-Ab-1/ GM-Tg-equg-MP1751-Ab-2Anti-Equine SYT9 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1751-Ab-1/ GM-Tg-hg-MP1751-Ab-2; GM-Tg-rg-MP1751-Ab-1/ GM-Tg-rg-MP1751-Ab-2;
GM-Tg-mg-MP1751-Ab-1/ GM-Tg-mg-MP1751-Ab-2; GM-Tg-cynog-MP1751-Ab-1/ GM-Tg-cynog-MP1751-Ab-2;
GM-Tg-felg-MP1751-Ab-1/ GM-Tg-felg-MP1751-Ab-2; GM-Tg-cang-MP1751-Ab-1/ GM-Tg-cang-MP1751-Ab-2;
GM-Tg-bovg-MP1751-Ab-1/ GM-Tg-bovg-MP1751-Ab-2; GM-Tg-equg-MP1751-Ab-1/ GM-Tg-equg-MP1751-Ab-2
Products NameAnti-SYT9 monoclonal antibody
Formatmab
Target NameSYT9
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-SYT9 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species SYT9 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1751
    Target NameSYT9
    Gene ID143425,60510,60564,710800,485365,101087096,536969,100070556
    Gene Symbol and SynonymsSYT9,Sytv
    Uniprot AccessionQ86SS6,Q925C0
    Uniprot Entry NameSYT9_HUMAN,SYT9_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000170743
    Target ClassificationN/A

    The target: SYT9, gene name: SYT9, also named as . Predicted to enable several functions, including calcium ion binding activity; phospholipid binding activity; and syntaxin binding activity. Predicted to be involved in calcium-ion regulated exocytosis; cellular response to calcium ion; and regulation of secretion by cell. Predicted to be located in clathrin-coated endocytic vesicle membrane. Predicted to be active in hippocampal mossy fiber to CA3 synapse; plasma membrane; and secretory vesicle. Predicted to be integral component of synaptic vesicle membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.